Jaeger M, et al. J. Clin. Oncol. (2004) cited as Ref 562 in DOI: 10.1038/s41392-020-0110-5 (Q9825)
Revision as of 22:04, 20 May 2020 by Admin (talk | contribs) (Created claim: Property:P93: Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I/II study, #quickstatements; #temporary_...)
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Jaeger M, et al. J. Clin. Oncol. (2004) cited as Ref 562 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Jaeger M
0 references
2004
0 references
J. Clin. Oncol.
0 references
22
0 references
Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I/II study (English)
0 references
